Home Newsfeeds Baird Maintains Outperform on Cardiff Oncology, Lowers Price Target to $6

Baird Maintains Outperform on Cardiff Oncology, Lowers Price Target to $6

Baird analyst Joel Beatty maintains Cardiff Oncology (NASDAQ:CRDF) with a Outperform and lowers the price target from $9 to $6.

byBenzinga Newsdesk

August 29, 2022

1 minute read

Baird analyst Joel Beatty maintains Cardiff Oncology (NASDAQ:CRDF) with a Outperform and lowers the price target from $9 to $6.

‘Do Bad Reviews Kill Companies?’: MKBHD Reacts After Humane AI Pin Video Sparks Concern On Social Media

By Rounak Jain

April 17, 9:07 AM

MKBHD, or Marques Brownlee, has kicked off a social media storm with Humane AI Pin review, weeks after his critical opinion of Ocean Fisker SUV.

FSRN

When Silicon Valley Meets Capitol Hill On AI’s Frontier: Behind Closed Doors

By AJ Fabino

September 13, 2:55 PM

In a closed-door session at Capitol Hill on Wednesday, an assembly of tech leaders, including Elon Musk, Mark Zuckerberg, Bill Gates and Sam Altman addressed the Senate on the issue of artificial intelligence (AI).

GOOG

Japan’s All Nippon Airways To Cut 30 Flights Per Day During January-March 2024: Here’s Why

By Shivani Kumaresan

October 31, 9:26 AM

Japan-based air transport and cargo services provider ANA Holdings Inc. (OTC: ALNPY) All Nippon Airways plans to begin a series of

ALNPY

Rezolute Q2 EPS $(0.26) Beats $(0.32) Estimate

By Michael Horton

February 10, 5:05 PM

Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.32) by 18.75 percent. This is a 67.5 percent increase over losses of $(0.80) per share from the same

RZLT

Baird Maintains Outperform on Cardiff Oncology, Lowers Price Target to $6

Related Posts

‘Do Bad Reviews Kill Companies?’: MKBHD Reacts After Humane AI Pin Video Sparks Concern On Social Media

When Silicon Valley Meets Capitol Hill On AI’s Frontier: Behind Closed Doors

Japan’s All Nippon Airways To Cut 30 Flights Per Day During January-March 2024: Here’s Why

Rezolute Q2 EPS $(0.26) Beats $(0.32) Estimate